AKUR8
Mutua Madrileña chooses Akur8 as its new pricing solution for its Non-Life insurance lines (motor, home and multi-risk) in Spain. This allows Akur8 to strengthen its presence in Spain by putting its innovative model at the service of the country's leading General Insurance company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005014/en/
Developed specifically for insurers, Akur8's solution empowers pricing teams to make better decisions faster by automating rate making through its proprietary algorithms powered by Transparent AI. Key benefits for insurers include accelerated speed-to-accuracy and market reactivity for immediate commercial impact, while maintaining full transparency and control over pricing models.
Mutua Madrileña, the leading insurer by turnover in Non-Life insurance in Spain, has chosen to implement Akur8's RISK, DEMAND and RATE modules to remain at the forefront in the predictive power of its pricing models, in the agility of updating rates and pricing new products, and to reinforce the consistency of its modeling process and results.
“We are really looking forward to starting this new collaboration with Mutua Madrileña, a key player in the Spanish insurance market. We are very proud to provide them with a best-in-class solution taking their pricing capabilities to new heights and bolster innovation at the core of the pricing process” stated Samuel Falmagne, CEO at Akur8.
“Reinforcing our footprint in Spain is a great milestone for Akur8’s global expansion. It strengthens our position as the up-and-coming pricing solution on the Spanish market and our relevance among large mutual insurers” noted Brune de Linares, Chief Customer Officer at Akur8.
"For Mutua Madrileña, working with Akur8's pricing solution will help us to further improve our time to market and continue to offer the best customer experience to our policyholders," commented Federico Vicioso, CTO of Mutua Madrileña.
About Akur8
Akur8 is revolutionizing insurance pricing with Transparent AI, boosting insurers’ pricing capabilities with unprecedented speed and accuracy across the pricing process without compromising on auditability or control.
Our modular pricing platform automates technical and commercial premium modeling. It empowers insurers to compute adjusted and accurate rates in line with their commercial strategy while materially impacting their business and maintaining absolute control of the models created, as required by regulators worldwide. With Akur8, time spent modeling is reduced by 10x, the models’ predictive power is increased by 10% and loss ratio improvement potential is boosted by 2-4%.
Akur8 already serves 50+ customers across 20+ countries, including AXA, Generali, Munich Re, Tokio Marine North America Services (TMNAS); specialty insurer Canopius and MGA Bass Underwriters; consulting partners Xceedance and Perr & Knight; and insurtechs Bought by Many and wefox. Over 700 actuaries use Akur8 daily to build their pricing models across all lines of business. Akur8’s strategic partnerships include Milliman, Duck Creek, Guidewire and Sapiens.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Virometix AG Announces Positive Data from Phase 1 Trial of V-212, a Fully Synthetic, Serotype-Independent Vaccine Development Candidate for the Prevention of Pneumococcal Disease8.1.2026 13:00:00 CET | Press release
V-212 was well tolerated and demonstrated an excellent safety profileRobust IgG responses were observed to all three antigens in the vaccineResults support further development of V-212 independently and in combination with approved pneumococcal conjugate vaccines (PCVs) Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced positive topline data from the Company’s Phase 1 trial of its lead asset V-212, a serotype-independent pneumococcal vaccine candidate, in development for the prevention of pneumococcal disease caused by Streptococcus pneumoniae (Spn) infections. The study evaluated safety and immunogenicity in healthy volunteers, with data demonstrating an excellent safety profile and robust immune responses across all three target antigens in the vaccine. Results support further development of V-212 independently and in combination with an approved PCV. “With the significant need for an effective serotype-independent vaccine, we ar
Abbelight Announces Successful Series B Investment led by AVANT BIO to Accelerate Imaging Innovation and Scale Adoption Across a Broader Customer Base8.1.2026 12:36:00 CET | Press release
Abbelight, a global leader and a pioneer in super-resolution microscopy end-to-end solutions, today announced a successful Series B financing round led by AVANT BIO, a growth equity firm focused on enabling technologies shaping tomorrow’s therapeutics. “With a decade of experience in the Life Science Research market, Abbelight has been transforming the way scientists see, quantify, and interpret all kinds of complex intracellular mechanisms. It’s now time to tailor our cutting-edge imaging toolbox to also address new key verticals, such as single cell phenotyping and mechanisms of action validation for drug discovery”, says Nicolas Bourg CTO and co-founder. “Big things happen at the nanoscale - and Abbelight enables researchers to visualize precise sub-cellular structures like never before”, said Daniella Kranjac, Founding General Partner at AVANT BIO. “Their breakthroughs in super-resolution microscopy and sample-to-insight workflows embody the kind of enabling technologies that accel
FGS Global launches 2026 Radar Report: "A Rewired World"8.1.2026 11:00:00 CET | Press release
The post-war global order is fragmenting into spheres of influence as strongman leadership and transactional relationships replace multilateral cooperation, according to FGS Global's Radar 2026 report released today. FGS Global’s Radar is based on 175 in-depth interviews with senior global leaders and policy experts from the worlds of business, politics, academia and media and wide ranging, nationally representative polling of approximately 20,000 people across the US, Canada, the member countries of the European Union and Japan. We are in a Rewired World reshaped by the collapse of multilateral consensus and the rise of strongman leadership over weakened institutions. US-China competition is intensifying across trade, technology and space while traditional alliances fracture. At the same time, AI-driven disruption is accelerating change, populist disruptors are challenging established systems and influence is atomizing as mainstream media and political parties lose ground. The implica
GEOLOG Acquires Quad Ltd and QO Inc. to Enhance Global Wellsite Geology and Pore Pressure Services8.1.2026 11:00:00 CET | Press release
Strategic acquisition deepens GEOLOG’s technical expertise and broadens service delivery worldwide GEOLOG International B.V. (“GEOLOG” or the “Company”), a leading independent provider of wellsite geosciences, drilling solutions and surface logging services to the energy industry, today announced the successful acquisition of Quad Ltd and QO Inc. (together, “Quad”). Quad is a long-standing provider of wellsite and operations geologists, along with advanced pore pressure and fracture gradient analysis services. This strategic bolt-on acquisition significantly enhances GEOLOG’s portfolio of advanced subsurface and drilling support services and solidifies its operational presence globally. GEOLOG and Quad have a history of successful collaboration on numerous international projects, serving a broad spectrum of energy clients. Integrating Quad’s highly experienced personnel and specialized technical capabilities will strengthen GEOLOG’s capacity to support clients in complex drilling envir
Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 10:03:00 CET | Press release
Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom